Our observation that combining pharmacological concentrations of drugs targeting the MYCN network can activate synthetic lethality in MYCN-amplified tumor cells suggests that this approach has the potential to be successfully translated in the clinic. The gene discussed is MYCN; the disease is neoplasm.